Product

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine

CAS No.：881202-45-5

Other grades of this product :

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Basic information

Product Name:	N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine
Synonyms:	N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine;CS-389;JNJ 26854165; JNJ26854165; JNJ-26854165;JNJ 26854165;SerdeMetan;JNJ-26854165 (SerdeMetan);JNJ 26854165 N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine;N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine JNJ 26854165
CAS:	881202-45-5
MF:	C21H20N4
MW:	328.41
EINECS:	200-256-5
Product Categories:	Inhibitors;Inhibitor
Mol File:	881202-45-5.mol

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Chemical Properties

solubility	insoluble in EtOH; insoluble in H2O; ≥14.8 mg/mL in DMSO
form	solid

Safety Information

HS Code

29339900

MSDS Information

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Usage And Synthesis

Uses

JNJ 26854165 is a p53 activator and HDM2 ubiquitin ligase (MDM2) inhibitor.

Biological Activity

jnj-26854165, also named as serdemetan, is originally developed as an activator of p53, is now regarded as a novel oral human double minute-2 (hdm-2) ubiquitin ligase antagonist. it can increase the level of hdm-2 client proteins, such as p53, by inhibiting the association of hdm-2-client protein complex with the proteosome. it is demonstrated potent anti-proliferative and apoptosis-inducing activity of jnj-26854165 in a broad range of p53 wild type and mutant tumor models. in vivo, jnj-26854165 may induce important differences in efs distribution when comparing to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable all xenografts.j. tabernero, l. dirix, p. schoffski, a. cervantes, j. capdevila, j. baselga, l. van beijsterveldt, h. winkler, s. kraljevic and s. h. zhuang. phase i pharmacokinetic (pk) and pharmacodynamic (pd) study of hdm-2 antagonist jnj-26854165 in patients with advanced refractory solid tumors. journal of clinical oncology (meeting abstracts) may 2009 vol. 27 no. 15s 3514malcolm a. smith, richard gorlick, e. anders kolb, richard lock, hernan carol, john m. maris, stephen t. keir, christopher l. morton, c. patrick reynolds, min h. kang, janine arts, tarig bashir, michel janicot, raushan t. kurmasheva, peter j. houghton. initial testing of jnj-26854165 (serdemetan) by the pediatric preclinical testing program. pediatric blood & cancer. volume 59, issue 2, pages 329–332, august 2012.

N-[2-(1H-Indol-3-yl)ethyl]-N'-(4-pyridinyl)-1,4-benzenediamine Preparation Products And Raw materials

Welcome！

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
+86-23-6139-8061 +86-13650506873
danny@chemdad.com sales@chemdad.com
www.chemdad.com
WhatsApp +86-13650506873